ResearcherSpanish National Cancer Research CentreActive in the last 2 years

Beatriz Salvador-Barberó

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3842-2383; OpenAlex author ID A5085194521. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent "in-tumour" chemotherapy to pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-024-02869-3 ↗
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2020.01.007 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Luned M. Badder · 1 shared paper, 2024 · strength 0.22
- Paper The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent "in-tumour" chemotherapy to pancr… DOI 10.1038/s41416-024-02869-3 ↗
Alan L. Parker · 1 shared paper, 2024 · strength 0.22
- Paper The αvβ6 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent "in-tumour" chemotherapy to pancr… DOI 10.1038/s41416-024-02869-3 ↗
Manuel M. Hidalgo · 1 shared paper, 2020 · strength 0.10
- Paper CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. DOI 10.1016/j.ccell.2020.01.007 ↗
Marcos Malumbres · 1 shared paper, 2020 · strength 0.10
- Paper CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. DOI 10.1016/j.ccell.2020.01.007 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.